Match!

Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease

Published on Jun 1, 2015in Alimentary Pharmacology & Therapeutics7.73
· DOI :10.1111/apt.13215
Pavit Luthra5
Estimated H-index: 5
(St James's University Hospital),
Laurent Peyrin-Biroulet59
Estimated H-index: 59
(French Institute of Health and Medical Research),
Alexander C. Ford Mrcp59
Estimated H-index: 59
(University of Leeds)
Abstract
Summary Background Anti-integrin antibodies are effective therapies for Crohn's disease (CD) and ulcerative colitis (UC). However, these drugs carry theoretical risks of opportunistic infection and malignancy. Aim To pool data from all placebo-controlled studies, to estimate risk of opportunistic infection or malignancy with anti-integrin antibodies. Methods MEDLINE, EMBASE and the Cochrane central register of controlled trials were searched (up to December 2014). Randomised placebo-controlled trials of anti-integrin antibodies in adults with active or quiescent CD or UC were eligible. Dichotomous data were pooled to obtain a relative risk (RR) of opportunistic infection or malignancy, with 95% confidence intervals (CIs). Results The search strategy identified 1579 citations, 12 of which were eligible (four trials of natalizumab, six of vedolizumab and two of etrolizumab). The RR of developing an opportunistic infection was not significantly higher with non-gut specific (2.34; 95% CI 0.05–108.72) or gut specific anti-integrin antibodies (1.55; 95% CI 0.16–14.83). The RR was generally higher in trials of non-gut specific anti-integrin antibodies with duration of therapy ≥52 weeks (RR = 15.00; 95% CI 0.86–261), but remained non-significant. The RR of malignancy was not elevated with non-gut specific (1.57; 95% CI 0.19–12.74) or gut specific anti-integrin antibodies (0.78; 95% CI 0.15–4.02). Conclusions Absolute numbers of opportunistic infections were higher with anti-integrin antibodies, but this difference is not statistically significant. There was no increased risk of malignancy detected. Long-term data in large prospective cohorts are needed to further assess this issue.
  • References (44)
  • Citations (34)
References44
Newest
#1Antje Timmer (University of Oldenburg)H-Index: 15
#2Petrease H Patton (UWO: University of Western Ontario)H-Index: 4
Last.John K MacDonald (Cochrane Collaboration)H-Index: 33
view all 5 authors...
309 CitationsSource
#1Yongjun Wang (UWO: University of Western Ontario)H-Index: 4
#2Claire E Parker (Cochrane Collaboration)H-Index: 3
Last.John K MacDonald (Cochrane Collaboration)H-Index: 33
view all 4 authors...
299 CitationsSource
#1Yongjun Wang (UWO: University of Western Ontario)H-Index: 4
#2Claire E Parker (Cochrane Collaboration)H-Index: 3
Last.John K MacDonald (Cochrane Collaboration)H-Index: 33
view all 5 authors...
321 CitationsSource
#1Nilesh Chande (London Health Sciences Centre)H-Index: 22
#2Petrease H Patton (UWO: University of Western Ontario)H-Index: 4
Last.John K MacDonald (Cochrane Collaboration)H-Index: 33
view all 5 authors...
213 CitationsSource
#1Man Cai WangH-Index: 4
#2Ling Yi ZhangH-Index: 3
Last.You Cheng ZhangH-Index: 5
view all 11 authors...
35 CitationsSource
#1Bruce E. Sands (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 70
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 95
Last.Stephen B. Hanauer (U of C: University of Chicago)H-Index: 104
view all 14 authors...
322 CitationsSource
#1Stephen J. BickstonH-Index: 19
#2Brian W. Behm (UVA: University of Virginia)H-Index: 8
Last.Brian G. Feagan (Robarts Research Institute)H-Index: 95
view all 7 authors...
32 CitationsSource
#1Severine Vermeire (Katholieke Universiteit Leuven)H-Index: 110
#2Sharon O'Byrne (Genentech)H-Index: 10
Last.Paul Rutgeerts (Katholieke Universiteit Leuven)H-Index: 138
view all 25 authors...
226 CitationsSource
#1Angelika Na (Royal Melbourne Hospital)H-Index: 1
#2Nick Hall (Royal Melbourne Hospital)H-Index: 1
Last.John King (Royal Melbourne Hospital)H-Index: 22
view all 4 authors...
10 CitationsSource
#1Reuben Valenzuela (UIC: University of Illinois at Chicago)H-Index: 2
#2John H. Pula (UIC: University of Illinois at Chicago)H-Index: 20
Last.Jorge C. Kattah (UIC: University of Illinois at Chicago)H-Index: 13
view all 5 authors...
18 CitationsSource
Cited By34
Newest
#1Bénédicte Caron (UDS: University of Strasbourg)H-Index: 2
#2Laurent Peyrin-Biroulet (University of Lorraine)H-Index: 59
Last.Aurelien AmiotH-Index: 20
view all 24 authors...
2 CitationsSource
#1Christopher A. Lamb (Newcastle University)H-Index: 19
#2Nicholas A. Kennedy (University of Exeter)H-Index: 26
Last.A. Barney Hawthorne (University Hospital of Wales)H-Index: 5
view all 29 authors...
3 CitationsSource
#1Konstantinos H. Katsanos (RMIT: RMIT University)H-Index: 6
#2Konstantinos Papamichael (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 18
Last.Adam S. Cheifetz (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 34
view all 5 authors...
11 CitationsSource
#1Steve C. L. Lin (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 11
#2Alexander Goldowsky (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 2
Last.Adam S. Cheifetz (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 34
view all 4 authors...
Source
#1Yoichi Kakuta (Tohoku University)H-Index: 19
#2Yosuke Kawai (Tohoku University)H-Index: 12
Last.Atsushi Masamune (Tohoku University)H-Index: 47
view all 36 authors...
2 CitationsSource
#1Benjamin Click (Cleveland Clinic)H-Index: 1
#2Miguel Regueiro (Cleveland Clinic)H-Index: 3
3 CitationsSource
#1Charlotte Lichnog (FAU: University of Erlangen-Nuremberg)H-Index: 1
#2Sha Klabunde (Genentech)H-Index: 1
Last.Sebastian Zundler (FAU: University of Erlangen-Nuremberg)H-Index: 10
view all 16 authors...
1 CitationsSource
#1Kara De Felice (LSU: Louisiana State University)
#2Sunanda Kane (Mayo Clinic)H-Index: 32
Source
#1Benjamin Click (Cleveland Clinic)H-Index: 1
#2Miguel Regueiro (Cleveland Clinic)H-Index: 3
1 CitationsSource
Source